Venetoclax-Related Neutropenia in Leukemic Patients: A Comprehensive Review of the Underlying Causes, Risk Factors, and Management

Venetoclax is a Bcl-2 homology domain 3 (BH3) mimetic currently approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) that has proven to be highly effective in reinstating apoptosis in leukemic cells through the highly selective inhibition of the anti-apop...

詳細記述

書誌詳細

主要な著者:	Laura Giuseppina Di Pasqua, Murwan Mahmoud Abdallah, Fausto Feletti, Mariapia Vairetti, Andrea Ferrigno
フォーマット:	Artigo
言語:	Inglês
出版事項:	MDPI AG 2024-04-01
シリーズ:	Pharmaceuticals
主題:	venetoclax neutropenia AML CLL BH3 mimetic Bcl2
オンライン･アクセス:	https://www.mdpi.com/1424-8247/17/4/484
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!